Respiratory Pathogen Diagnostic Report

Patient:	**Physician:**	**Date Collected:** 6/2/2023 11:22 AM
DOB:	**NPI:**	**Date Received:**
Gender	**Practice:**	**Date Reported:**
Passport:	**Phone:**	**Sample Type:**
MRN:		**Sample Number:** B22K0001

Final Report

1. About this Report

This LabLynx report contains results of SARS-like coronaviruses 2019-nCoV performed through real-time PCR (rRT-PCR) for nucleic acid analysis. The test is designed to detect 2019-nCoV in respiratory specimens.

2. Molecular Diagnostic Results

Test Performed	Test Result
---	0

A positive test result for 2019-nCoV indicates that RNA from 2019-nCoV was detected, and the patient is presumptively infected with 2019-nCoV and presumed to be contagious. Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making a final diagnosis and patient management decisions. Patient management should follow current CDC guidelines.

The SARS-CoV-2 Real-Time PCR Test, validated at Fake Testing Labs, has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks to patients could indicate the following: a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other potentially 2019-nCoV infected patients, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or threapy, or other unintended adverse effects.

A negative test result for this test means that 2019-nCoV RNA was not present in the specimen above the limit of detection. However, a negative result does not rule out 2019-nCoV infection and should not be used as the sole basis for treatment or patient mangement decisions. A negative result does not exclude the possibility of 2019-nCoV infection.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patients recent exposures and the presence of clinical signs and symptoms consistent with 2019-nCoV infection. The possiblity of a false negative result should especially be considered if the patient's recent exposures or clinical presentation indicate that 2019-nCoV infection is likely, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. If 2019-nCoV infection is still suspected based on exposure history together with other clinical findings, re-testing should be considered in consultation with public health authorities.

The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimem. This test was developed and its performance characteristics determined by LabLynx. It has not been cleared or approved by the US Food and Drug Administration.